.png?width=1387&height=800&name=Scout_Logo_RGB%20(1).png){kind=logo}
European Biotech Act: EU-X-CT shows us where cross-border trial access gets stuck
The appeal of decentralized clinical trials is easy to understand. When certain study activities...
High-volume clinical trial payments are often treated as a technical question–whether a system can...
Sponsors and CROs may plan a European clinical trial by region. But participants experience it...
Most organizations involved in clinical trials would describe their financial operations as...
Participants don’t care how your vendor stack is organized Clinical trials are organized through...
How does scaling impact outsourced clinical trial services? Scaling increases operational...
The Scout Summit returned for its second year this April, bringing Scout Clinical Project Managers,...
Late-stage operational scramble costs more than teams expect “Later” has a funny way of becoming...
Participant payments should not become site work Participant payments sound simple until the...
DALLAS, – May 7, 2026 – Scout, a premier provider of clinical trial services, today announced that...
Global studies change how payments behave.
This won’t come as a surprise to anyone in the industry, but attendance at investigators’ meetings...
Something always comes up.
High-volume sites are short on time, not tools Most sites already have systems in place to manage...
Most engagement strategies with sites begin after the most important decisions have already been...
A pediatric participant is midway through a 12-visit study that requires international travel,...
Attendance at investigators’ meetings isn't guaranteed. Principal investigators and site staff are...
The problem as it actually shows up Clinical trial payment issues are usually described as delays....
Scout has made near-term and net-zero commitments through the Science Based Targets initiative...